Navigation Links
Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
Date:3/24/2008

Five Year Contract with Canadian Division of Global Pharmaceutical Company

Endorses Value of Millennium's Targeted Nutritional Supplement

BASKING RIDGE, N.J., March 24 /PRNewswire/ Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB: MBTG) announced today that it has entered into a five-year exclusive distribution agreement for Resurgex(R), its nutritional formula for immuno- comprised patients, with Ferring Inc. of Canada, a division of Ferring S.A.

Under the distribution agreement Ferring will have the exclusive right to use the Resurgex trademarks and sell the Resurgex line of products in Canada. Ferring will be responsible for the marketing, distribution and sales efforts throughout Canada putting Resurgex(R) into the premium Enteral Nutritional Market. Ferring will purchase all products from Millennium Biotechnologies and will promote Resurgex to various specialist groups throughout Canada.

Richard Jeysman, President of Ferring Canada stated "Resurgex's proven success in the U.S. unequivocally demonstrates this product's ability to help immuno-compromised patients better deal with various disorders such as cancer, and afflictions of the gastrointestinal tract."

"Given the exhaustive evaluation, which they have conducted, and the size of their investment, this is a significant step for Millennium Biotechnologies in the international commercialization of our product line" stated Mark C. Mirken, President and Chief Operating Officer of Millennium Biotechnology.

Ferring S.A. is a Swiss-based, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, fertility and urology.

About Millennium:

Millennium's six marketed products form the Company's advanced line of nutritional formulas. Resurgex Select(R) is a w
'/>"/>

SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Millennium Over-Delivers on 2007 Goals and Financial Guidance
2. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
3. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
4. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
5. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
6. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
7. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
8. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
9. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
10. Life Sciences Leader Joins Millennium Board of Directors
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: IPXL).  Such investors are advised to contact ... 888-476-6529, ext. 237. The investigation concerns whether ... violated Sections 10(b) and 20(a) of the Securities Exchange ... 2014, Impax Laboratories, Inc. (the "Company") issued a press ...
(Date:7/29/2014)... 29, 2014 According to the ... Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud ... & Trends to 2018", published by MarketsandMarkets, analyzes and ... such as North America , ... and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, applauds the Editorial ... a strong position in opposition to current federal ... 2014 publication.  The New York Times also announces ... week exploring the issue called "High Time:  An ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... First Capability To Rapidly Identify Five Candida ... Positive Blood Cultures In One Test, WOBURN, ... FDA 510(k) clearance of the Yeast Traffic Light ... positive blood cultures. The,Yeast Traffic Light(TM) is the ...
... 23 Affitech AS, the Norwegian human,antibody ... accomplished the,second milestone in its research and ... recombinant antibodies against an unnamed oncology,target. Affitech ... Antibody,Screening) system that included its proprietary antibody ...
... 22, 2008 -- Chemists at Rice University have discovered ... tiny, wand-like nanoparticles that are being studied in dozens ... disease and improving electronic viewscreens. , "The content of ... is only about 20 percent," said lead researcher Eugene ...
Cached Biology Technology:AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2Purifying nanorods: Big success with tiny cleanup 2
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the ... of researchers including the labs headed by Professors Neelima ... of Plant Biology. The new genome information may help ... published July 27 in the journal Nature Genetics ... Aachen University in Germany. The UC Davis labs carried ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... buzzing around your plate. Its color and motion could both influence ... might decide it was a bee and move away. Conversely, you ... insect away. You perceive both color and motion, and decide based ... heartbeat. The mystery is how. In an article published November ...
... A human clinical study of older adults has demonstrated ... dietary supplement created by Natura Therapeutics, Inc., showed ... individuals taking a placebo. Cognition includes processes such as ... The company,s study, Nutraceutical Intervention Improves Older Adults, Cognitive ...
... early infancy may be a key to early identification of ... of Mental Health (NIMH), part of the National Institutes of ... the study reveals the earliest sign of developing autism ever ... first two to six months of life. "Autism ...
Cached Biology News:Stanford researchers surprised to find how neural circuits identify information needed for decisions 2Stanford researchers surprised to find how neural circuits identify information needed for decisions 3Stanford researchers surprised to find how neural circuits identify information needed for decisions 4Stanford researchers surprised to find how neural circuits identify information needed for decisions 5Natura Therapeutics product shown to improve decision making skills in older adults 2Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human LAIR2 Biotinylated Affinity Purified PAb...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: